Egis is a leading Hungarian generic pharmaceutical company with over 110 years of experience. In 2024/2025 financial year, Egis Group generated net sales of EUR 773 million. We cover the full value chain—from R&D and API/FP manufacturing to marketing in 60+ countries. At Egis, besides simple generics, we deliver value-added generic and highly potent products through advanced chemistry, streamlined production, and strong IP expertise. Our portfolio includes 656 products focused on cardiovascular, CNS, diabetes, dermatology, oncology and wound care.
